Amyloid precursor protein (APP) is a large protein that sits in the membranes of cells throughout the body, most abundantly in the brain. It plays important roles in how neurons grow, form connections, and survive. APP became one of the most studied proteins in neuroscience because when it gets cut in a specific way, it produces a small, sticky fragment called amyloid beta, the peptide that accumulates into plaques in the brains of people with Alzheimer’s disease.
How APP Is Built
APP is a transmembrane protein, meaning it spans the cell membrane once with a large portion extending outside the cell and a shorter tail reaching into the cell’s interior. The section that crosses the membrane forms a long spiral-shaped structure (called an alpha-helix) roughly 40 angstroms long, anchoring the protein in place. A second, shorter helix lies along the membrane surface, connected to the transmembrane segment by a flexible loop.
The protein comes in three major forms produced by the same gene through alternative splicing: versions with 695, 751, or 770 amino acids. The 695-amino-acid form is the one predominantly found in neurons. The two longer forms contain an extra domain that inhibits protein-cutting enzymes and are expressed more broadly across other tissues. The APP gene itself sits on chromosome 21.
What APP Does in the Brain
Despite its reputation as the source of Alzheimer’s plaques, APP has several beneficial jobs. Its most consistent role is as a growth-supporting factor for neurons. APP localizes to the tips of growing nerve fibers, where it helps guide their extension toward other cells. It also contributes to synapse formation, the process by which neurons build the connections they use to communicate. In experimental models, removing or reducing APP leads to abnormal branching of nerve cell projections and weakened signaling at synapses, including reduced long-term potentiation, the cellular mechanism underlying learning and memory.
APP also functions in cell adhesion, helping neurons stick to their neighbors and to the structural scaffolding around them. This adhesion activity likely supports both the initial wiring of the brain during development and the ongoing maintenance of neural circuits in adults.
Where APP Is Found Outside the Brain
APP is not exclusive to the brain. Platelets, the small blood cells involved in clotting, are the second-highest source of APP in the body, containing levels comparable to brain tissue. Platelets carry the longer APP forms (751 and 770 amino acids) that include the enzyme-inhibitor domain. Other tissues, including the kidneys and cells of the immune system, also produce APP, though in smaller quantities. This widespread expression suggests APP has basic cellular functions beyond its neuronal roles, though the brain remains the focus of research because of the Alzheimer’s connection.
Two Ways APP Gets Cut
The fate of APP depends on which enzymes cut it first. There are two competing pathways, and the balance between them has major implications for brain health.
In the non-amyloidogenic pathway, an enzyme called alpha-secretase cuts APP right through the middle of the amyloid beta region. This destroys the amyloid beta sequence so it can never form, and it releases a soluble fragment (sAPP-alpha) into the space outside the cell. This fragment has neuroprotective properties, supporting cell survival and healthy signaling.
In the amyloidogenic pathway, a different enzyme called beta-secretase makes the first cut at a different spot, preserving the amyloid beta sequence intact. A second enzyme, gamma-secretase, then cuts from the membrane side, releasing the amyloid beta peptide. Depending on exactly where gamma-secretase cuts, the resulting fragment is either 40 or 42 amino acids long.
An important distinction: neurons tend to favor the beta-secretase pathway, producing more amyloid beta, while non-neuronal cells and platelets preferentially use the alpha-secretase pathway. This is one reason amyloid beta accumulation is primarily a brain problem.
Why the Amyloid Beta 42/40 Ratio Matters
Not all amyloid beta is equally dangerous. The 42-amino-acid version is slightly longer and much stickier than the 40-amino-acid version, making it far more prone to clumping into the plaques seen in Alzheimer’s disease. What drives disease progression is not simply how much total amyloid beta the brain produces, but the ratio of the 42 form to the 40 form.
Research using human neural cells has shown that a high ratio of amyloid beta 42 to 40 tightly correlates with the accumulation of tangled tau protein, another hallmark of Alzheimer’s. Cells with mutations that push the ratio higher develop robust tau pathology, while cells with mutations that lower the ratio do not. Over 200 known familial Alzheimer’s mutations increase this ratio, reinforcing its central role in the disease process. Even neighboring healthy neurons exposed to cells producing a high 42/40 ratio develop tau tangles, demonstrating that the toxic effects can spread between cells.
APP Gene Mutations and Early-Onset Alzheimer’s
Mutations in the APP gene are one cause of familial Alzheimer’s disease, a rare inherited form that strikes before age 65. The most common of these swaps one amino acid for another at position 717 of the protein. These mutations work by either increasing total amyloid beta production or shifting the cut site of gamma-secretase so it generates more of the sticky 42-amino-acid version.
More than half of all known familial APP mutations fall within or near the transmembrane domain, the stretch of protein embedded in the cell membrane. This makes sense because that domain is exactly where gamma-secretase makes its cut. Even small changes in the shape or flexibility of this region can redirect the enzyme’s cutting pattern, tipping the 42/40 ratio toward disease. The location of the APP gene on chromosome 21 also explains why people with Down syndrome, who carry three copies of chromosome 21, have a markedly higher risk of Alzheimer’s: the extra gene copy means more APP and, consequently, more amyloid beta.
APP as a Therapeutic Target
Because APP sits at the very start of the chain that produces amyloid beta, it has long been considered an attractive point of intervention. Reducing APP levels or shifting its processing away from the amyloidogenic pathway would, in theory, lower amyloid beta production across all forms of Alzheimer’s, not just familial cases. Strategies under investigation include promoting alpha-secretase activity to favor the protective pathway, inhibiting beta-secretase or gamma-secretase to block amyloid beta release, and using small regulatory molecules to dial down APP production at the genetic level. The challenge has been doing this without disrupting APP’s beneficial functions in synapse maintenance and neuronal health.